Lofexidine for Management of Opioid Withdrawal With XR-NTX Treatment
Status:
Completed
Trial end date:
2021-01-29
Target enrollment:
Participant gender:
Summary
This is an open-label pilot trial to evaluate the safety and tolerability of lofexidine in
the management of opioid withdrawal symptoms while initiating outpatient treatment with
naltrexone. The initiation procedure will be a flexible detoxification lasting 2 to 10 days
concluding with the injection of XR-Naltrexone (Vivitrol). Vivitrol is a long-acting
injection that contains enough medicine to last for one month blocking the effects of
opioids.